摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5′-azide-3′-O-tert-butyldimethylsilyl deoxythymidine | 132101-17-8

中文名称
——
中文别名
——
英文名称
5′-azide-3′-O-tert-butyldimethylsilyl deoxythymidine
英文别名
1-((2R,4S,5R)-5-(azidomethyl)-4-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;5'-deoxy-5'-azido-3'-O-(tert-butyldimethylsilyl)thymidine;5'-azido-3'-O-t-butyldimethylsilyl-5'-deoxythymidine;1-[(2R,4S,5R)-5-(azidomethyl)-4-[tert-butyl(dimethyl)silyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
5′-azide-3′-O-tert-butyldimethylsilyl deoxythymidine化学式
CAS
132101-17-8
化学式
C16H27N5O4Si
mdl
——
分子量
381.507
InChiKey
HAXBFMMOEDAFCB-YNEHKIRRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.83
  • 重原子数:
    26
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    82.2
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5′-azide-3′-O-tert-butyldimethylsilyl deoxythymidinetetra-n-butylammoniumfluoride trihydrate 作用下, 以 四氢呋喃 为溶剂, 反应 12.0h, 以89%的产率得到5-叠氮基-5-脱氧胸腺嘧啶脱氧核苷
    参考文献:
    名称:
    通过 CuI 催化的环加成合成三唑连接的吗啉代寡核苷酸†
    摘要:
    使用 Cu I催化的 (3 + 2) 叠氮化物-炔烃环加成 (CuAAC) 反应合成三唑连接的吗啉代 ( TL MO) 寡核酸。修饰的 DNA 类似物通过固相合成被整合到 13-mer 序列中。紫外熔解实验表明,TL MO 修饰比相应的TL DNA 修饰产生更高的T m值。
    DOI:
    10.1039/c6ob00007j
  • 作为产物:
    描述:
    参考文献:
    名称:
    通过 CuI 催化的环加成合成三唑连接的吗啉代寡核苷酸†
    摘要:
    使用 Cu I催化的 (3 + 2) 叠氮化物-炔烃环加成 (CuAAC) 反应合成三唑连接的吗啉代 ( TL MO) 寡核酸。修饰的 DNA 类似物通过固相合成被整合到 13-mer 序列中。紫外熔解实验表明,TL MO 修饰比相应的TL DNA 修饰产生更高的T m值。
    DOI:
    10.1039/c6ob00007j
点击查看最新优质反应信息

文献信息

  • Oligonucleotide analogues containing internucleotide C3′-CH2-C(O)-NH-C5′ bonds
    作者:S. V. Kochetkova、A. M. Varizhuk、N. A. Kolganova、E. N. Timofeev、V. L. Florent’ev
    DOI:10.1134/s106816200902006x
    日期:2009.3
    interaction of 3'-deoxy-3'-carboxylmethylribothymidine-2',3'-lactone obtained by hydrolysis of 2'-O-acetyl-5'-O-benzoyl-3'-deoxy-3'-ethoxycarboxylmethylribothymidine with 5'-deoxy-5'-amino-3'-O-(tert-butyldimethylsilyl)thymidine. After standard manipulations with protective groups, the dinucleoside was converted into 3'-O-(2-cyanoethyl-N,N'-diisopropylphosphoroamidite), which was used for the synthesis
    通过3'-脱氧-3'-羧基甲基核苷嘧啶-2',3'-内酯的相互作用,合成了带有酰胺间C3'-CH2-C(O)-NH-C5'键的二核苷。 -O-乙酰基-5'-O-苯甲酰基-3'-脱氧-3'-乙氧基羧基甲基核糖嘧啶和5'-脱氧-5'-氨基-3'-O-(叔丁基二甲基甲硅烷基)胸苷。用保护基进行标准操作后,将二核苷转化为3'-O-(2-氰基乙基-N,N'-二异丙基亚磷酰胺),将其用于在自动合成仪上合成修饰的寡核苷酸。测量了由修饰的和互补的天然寡核苷酸形成的双链解链曲线,并计算了双链形成的解链温度和热力学参数。
  • Synthesis and antiretrovirus properties of 5'-isocyano-5'-deoxythymidine,5'-isocyano-2',5'-dideoxyuridine,3'-azido-5'-isocyano-3',5'-dideoxythymidine, and 3'-azido-5'-isocyano-2',3',5'-trideoxyuridine
    作者:Johann Hiebl、Erich Zbiral、Jan Balzarini、Erik De Clercq
    DOI:10.1021/jm00108a028
    日期:1991.4
    were prepared by three different ways. In the most direct synthesis 3 and 4 were transformed to the 2,3'-anhydro-5'- azidonucleosides 17 and 18 by using TPP/DEAD; following the reaction with TPP/HCO2COCH3 gave 19 and 20. Nucleophilic opening reaction with LiN3 yielded the 3'-azido-5'-formylamino derivatives 21 and 22. Dehydration to 3'-azido-5'-isocyano-3',5'-dideoxythymidine (23) and 3'-azido-5'-isocyano-2'
    通过用TPP / DEAD / HN3处理胸苷和2'-脱氧尿苷获得5'-叠氮核苷3和4。将3'-O-甲硅烷基化的5'-叠氮基5'-脱氧胸苷5和相应的2'-脱氧尿苷衍生物6转化成甲酰胺(分别为7和8),并脱水成受保护的5'-异氰基衍生物9和10; 脱保护得到5′-异氰基-5′-脱氧胸苷(11)和5′-异氰基-2′,5′-二脱氧尿苷(12)。胸苷和2'-脱氧尿苷的2,3'-脱水-5'-甲酰胺衍生物(分别为19和20)是通过三种不同的方法制备的。在最直接的合成中,使用TPP / DEAD将3和4转化为2,3'-脱水-5'-叠氮核苷17和18。与TPP / HCO2COCH3反应后,得到19和20。与LiN3的亲核开放反应产生3'-叠氮基-5'-甲酰氨基衍生物21和22。脱水成3'-叠氮基-5'-异氰基-3',5'-二脱氧胸苷(23)和3'-叠氮基-5用甲苯磺酰氯/吡啶获得“-异氰基-2”,3”,
  • Novel thymidine-based organogelators and their gelation behaviours
    作者:Young Ji Yun、Sun Min Park、Byeang Hyean Kim
    DOI:10.1039/b210822d
    日期:2003.1.7
    We report on a synthesis of novel thymidine based organogelators and a study of their gelation types in relation to structure and solvent, using various data acquired through FT-IR, SEM images and differential scanning calorimetry.
    我们报告了一种新型胸苷基有机凝胶剂的合成,并研究了它们的凝胶类型与结构及溶剂之间的关系,使用了通过傅里叶变换红外光谱、扫描电子显微镜图像和差示扫描量热法获得的各种数据。
  • Oligonucleotide analogs with sulfamate linkages
    申请人:The Dupont Merck Pharmaceutical Company
    公开号:US05470967A1
    公开(公告)日:1995-11-28
    Oligonucleotides possessing at least one sulfamate or sulfamide internucleotides linkages. These compounds can be used as specific hybridization probes to detect complementary nucleic acid sequences.
    具有至少一个磺酰胺或磺酸酯核苷酸间键的寡核苷酸。这些化合物可用作特异性杂交探针,用于检测互补的核酸序列。
  • Oligonucleotide analogues containing phosphate diester linkage
    申请人:Sanofi
    公开号:US05677439A1
    公开(公告)日:1997-10-14
    The present invention relates to compounds, compositions and methods for inhibiting gene expression. The compounds of this invention comprise 1) oligonucleoside sequences of from about 6 to about 200 bases having a three atom internucleoside linkage or 2) oligonucleotide sequences of from about 9 to about 200 bases having a diol at either or both termini.
    本发明涉及抑制基因表达的化合物、组成物和方法。本发明的化合物包括1)由大约6到大约200个碱基组成,具有三个原子的核苷酸序列,或2)由大约9到大约200个碱基组成,两端具有二醇基团的寡核苷酸序列。
查看更多

同类化合物

鲁西他滨 化合物 T14195 [1,1'-联苯基]-2,3,3',4,4',5'-六醇 [(2R,3R,5S)-3-(氨基甲基)-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]N-[[(2R,3S,5R)-3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]氨基甲酸酯 9-(2-S-苯甲基-5-脱氧-2-硫代五呋喃糖基)-9H-嘌呤-6-胺 5-脱氧胸苷 5-脱氧-5-[(碘乙酰基)氨基]-胸腺嘧啶脱氧核苷 5-碘-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-2,5-二脱氧腺苷酸 5-叠氮基-5-脱氧胸腺嘧啶脱氧核苷 5-三氟乙酰氨基-5-脱氧胸腺嘧啶脱氧核苷 5'-脱氧-5'氟胸苷 5'-脱氧-5'-{[4-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-{[3-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-[4-苯基-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(吡啶-3-基)-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(4-氟苯基)-(1,2,3)三唑-1-基]胸苷 5'-硫代-胸苷3',5'-二乙酸酯 5'-溴乙酰氨基-5'-脱氧胸苷 5'-氨基-5-碘-2',5'-二脱氧尿苷 2-氯-N-[[3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]乙酰胺 2,5-二脱氧腺苷 2',5'-二脱氧尿苷 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]嘧啶-2,4-二酮 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]-5-甲基嘧啶-2,4-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)嘧啶-2,4(1H,3H)-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)-5-碘嘧啶-2,4(1H,3H)-二酮 1-citosin-1-yl-1,2,5-trideoxy-α-L-threo-pentofuranos-4-yloxymethylphosphonic acid 9-[2,5-dideoxy-2-fluoro-5-[N-(N-2-hydroxybenzoyl)sulfamoyl]amino-β-D-ribofuranosyl]adenine triethylammonium salt 5'-amino-2',5'-dideoxy-2'-fuorouridine 1-(5'-deoxythymidin-5'-yl)-4-[methyloxycarbonyl-(2'-deoxy-2',2'-difluorocytidin-4N-yl)]-1H-1,2,3-triazole 2',5'-dideoxy-2'-(3,5-dimethoxybenzamido)-5'-(cyclohexylacetamido)adenosine 2',5'-dideoxy-2'-(3'',5''-dimethoxybenzamido)-5'-(diphenylacetamido)adenosine 2',5'-dideoxy-5'-(hydroxyethylthio)adenosine 1-(5-azido-2,5-dideoxy-2-fluoro-β-D-arabinofuranosyl)-5-ethyluracil 1-(5'-deoxythymidin-5'-yl)-4-[methyl-(2'-deoxy-2',2'-difluorocytidin-4N-yl)]-1H-1,2,3-triazole 4′-C-azidomethyl-2′-deoxy-2′-fluorouridine 2',5'-dideoxy-6-thioguanosine thymidylyl (3'-5') 5'-seleno-5'-deoxythymidine 3'-O-(t-butyldimethylsilyl)-4'-α-methylthymidine (E)- and (Z)-5-(2-bromovinyl)-1-(5-chloro-2,5-dideoxy-β-D-erythro-pentofuranosyl)-5-methyl-4-(1,2,4-triazol-1-yl)pyrimidin-2(1H)-one N-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranos-5-yl>succinamic acid N-butyl-N'-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranose-5-yl>maleamide N-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranos-5-yl>maleamic acid 4'-chloromethyl-2'-deoxy-2',2'-difluorocytidine 4'-chloromethyl-2'-deoxy-2'-fluoro-3'-O-(L-valinyl)cytidine dihydrochloride 5'-deoxy-5'-{4-[2-(3-oxo-3H-benzo[f]chromen-1-yl)acetamidomethyl]-1H-1,2,3-triazol-1-yl}thymidine N6-benzoyl-3'-O-t-butyldimethylsilyl-5'-sulfamoylazido-2',5'-dideoxyadenosine N-{9-[(2R,4S,5R)-5-(Acetylamino-methyl)-4-hydroxy-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide